India, Jan. 23 -- Novo Medi Sciences (Novo Group) has announced the launch ofNEXIPOX PLUS(R), the most recent innovation in Varicella vaccine since decades. NEXIPOX PLUS(R) has been developed with a clear focus onaddressing the unique clinical, environmental, and operational needs of Indian patients and healthcare settings, making Novo Medi Sciences theonly company to proactively upgrade varicella vaccine specifically for India.

Live attenuated varicella vaccines are inherently thermolabile, making formulation stability and potency retention critical to ensuring effective immunisation outcomes. Recognising the challenges posed by real-world Indian conditions, NEXIPOX PLUS(R) has been developed with2X trehalose-based stabiliser system, re...